These data indicate that CRC cells upregulate SLC7A11 to support cancer growth under oxidative stress, suggesting a rationale for elesclomol‐induced SLC7A11 downregulation for the treatment of CRC. Here, SLC7A11 is linked to colorectal carcinoma.